Nimotuzumab with chemoradiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called nimotuzumab combined with standard chemotherapy and radiation for patients with esophageal cancer. It may help improve treatment effectiveness for those whose cancer has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a type of esophageal cancer called squamous cell carcinoma.
- You cannot have had any previous treatment for this cancer, such as surgery, radiation, or chemotherapy.
- You should be active and able to care for yourself (a score of 70 or more on a standard health scale).
- Your blood counts and organ function (like liver and kidneys) need to be within a certain healthy range.
- You cannot have other active cancers or an infection like tuberculosis or hepatitis.
- The cancer should not have spread to distant organs like the lungs, liver, or bones.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
This trial tests a drug called nimotuzumab combined with radiation therapy for older adults (65+) with advanced head and neck cancer. It aims to help control the cancer when chemotherapy is not an option.
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a targeted drug (nimotuzumab) combined with radiation therapy for older adults with cervical cancer. The goal is to improve treatment outcomes for those who cannot tolerate chemotherapy.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.